AcelRx Pharmaceuticals (ACRX) Stock Discussions on Social Media

NOTE DSUVIA ad is "Efficiently Delivered" ad... (click yes Professional)! Also SAFETY WARNING, BLACK BOX WARNINGS... so OLD 2019 "TONGUE & DONE" (last used) a thing of the PAST (last used in 2019, gee)!https://www.dsuvia.com/EFFECTIVE PAIN RELIEF,Efficiently Delivered.1,2DSUVIA is indicated for the management of acute pain,severe enough to require an opioid analgesic and for which alternative treatments are inadequate, in adults. DSUVIA is for use in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments.Please see Limitations of Use and BOXED WARNING under Important Safety Information below.

AcelRx's sublingual DSUVIA the ONLY Acute Pain drug in a medical setting that does NOT require an IV to administer...! 1 out 9 patients with DVA too difficult to administer an IV...Risk factors associated with difficult venous access in adult ED patientsConclusions: Nearly 1 of every 9 to 10 adults in an urban ED had DVA (difficult venous access). Diabetes, IV drug abuse, and sickle cell disease were found to be significantly associated with DVA.

I see some people on other forums that think Vincent simply acquired a million shares.. Nope, the company has to perform first. He'll be able to exercise a third if the share price maintains $4/share for 30 days, a third for $5, and a third for $6. I'm paraphrasing, please read the latest Form 4, I linked it below.

More low ball bids this morning. I'll be a buyer today.

Phase 4 Results coming soon, perhaps the Best of the Best medical facilities using DSUVIA:"Cleveland Clinic (No. 2 hospital in the nation; No. 1 hospital for heart care in U.S. News & World Report’s “2020-21 Best Hospitals” rankings.)" "Brigham and Women's Hospital and Harvard Medical School." IMPRESSIVE comes to mind:Plastic Surgery - February 17, 2021The principal investigator, Dr. Hisham Seify, is a board-certified plastic surgeon and the past-president of the Orange County Society of Plastic Surgeons*Hisham Seify, M.D., PhD, FACS wins Top Plastic Surgeon West and Top Aesthetic Doctor in the Aesthetic Everything® 2020 Aesthetic and Cosmetic Medicine Awards. This year's 2020 Aesthetic Everything® Awards tapped winners from over 40,000 votes cast.*Cardiac Surgery - Jan. 19, 2021University Hospitals (UH) Cleveland Medical Center to evaluate the postoperative use of its opioid drug Dsuvia in a prospective cohort of patients undergoing cardiac surgery with cardiopulmonary bypass following a specialized enhanced recovery protocol.AcelRx shares rise after announcing investigator-initiated study of opioid drug DsuviaOrthopedic Surgery - August 27, 2020Cleveland Clinic has teamed with AcelRx Pharmaceuticals to study the effects of DSUVIA, a synthetic opioid tablet, on patients recovering from orthopedic surgery.A recent DSUVIA study noted a significant decrease in the amount of opioids used in the post-anesthesia care unit, according to Pamela Palmer, MD, PhD, co-founder and CMO of AcelRx Pharmaceuticals.Spine Surgery (results soon) - March 6, 2020Brigham and Women's Hospital for an investigator-initiated study led by Richard D. Urman MD, MBA, Associate Professor of Anesthesia and co-director of the Center for Perioperative Research at Brigham and Women's Hospital and Harvard Medical School. The study plans to examine the perioperative use of DSUVIA in the analgesic regimen for spine surgery.

"FDA requests that AcelRx cease any violations of the Food, Drug and Cosmetic Act and submit a written response within 15 days from the date of receipt of the letter addressing the concerns in the letter, listing all other promotional communications that contain statements such as those described in the letter, and explaining any plan for discontinuing use of such communications or for ceasing distribution of Dsuvia. If AcelRx fails to adequately address the concerns outlined in the warning letter, the FDA may take further regulatory action. The FDA is also requesting that AcelRx submit a comprehensive plan of action to distribute truthful, non-misleading, and complete corrective communications about the concerns discussed in the warning letter to the audience(s) that received the promotional communications."

SEE Notes 4 and 5 on latest form 4.. The options can be exercised only if the share price maintains $4/5/6 etc. Read it, it is a great sign of confidence.

I will HOLD until 500% upside based on this January 2021 Buy Recommendation:January 12, 2021: In line with his bullish stance, Folkes rates ACRX a Buy, and his $9 price target implies room for a stunning 552% upside potential in the next 12 months“With the launch of Dsuvia, we believe investor focus can now shift to launch metrics and peak sales potential for the product. As ACRX launches a true alternative to IV opioids, we expect investors to begin to appreciate the value of the product. We believe that Dsuvia offers an advancement in delivery of adequate pain treatment by eliminating the need for an invasive and time-consuming IV set-up in the emergency room, as well as an outpatient, or post-surgery, setting. Despite hospital launches taking time, we expect the uptake of Dsuvia to drive revenue upside beyond the Street's current estimates, which, in turn, could drive the stock higher from current levels,” Follked opined.

When will this stock be able to sustain a $3 pps?

DSUVIA is a DIRECT threat to Pfizer, and all big pharma NOTE: "100 Years"Aug. 19, 2020: "The standard of care for perioperative opioid administration has not been disrupted for over 100 years. We should no longer accept the rapid plasma fluctuations of IV bolus opioid administration as the status quo, as it impacts the patient's hemodynamic status and requires repeated redosing which ultimately results in higher overall opioid exposure"Dr. Christian Tvetenstrand, Chairman of Surgery and Director of Trauma, United Health Services Wilson Medical Center, New York. "I strongly believe this data on preoperative DSUVIA administration will result in a paradigm shift in pain management protocols across all ambulatory surgeries, as we have already seen significant cost savings due to less medical intervention and improved patient recovery."https://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-announces-publication-clinical-data

Well well, CEO Vince Form 4 out today, 1 million shares granted @ $4.00... Sell AcelRx say $20 (one day) = $16 million PROFIT! Greed is GOOD!

The FDA will issue a "Close-Out Letters" Re: this TONGUE & DONE" not used since 2019...AcelRx last used TONGUE & DONE in 2019, believe it's 2021. In AcelRx's 8K they said "The Company believes it can easily address these concerns without a material impact to the Company given the nature of the Promotional Materials and because the Company has not used the Banner Ad since late 2019, nor used the table drape that is part of the Tabletop Display since November 2019.... The Company intends to respond to the FDA within the timeframe requested in the Letter and seek guidance and clarification from the FDA on the concerns raised in the Letter"

Yep, now 500% upside based on this January 2021 Buy Recommendation:January 12, 2021: In line with his bullish stance, Folkes rates ACRX a Buy, and his $9 price target implies room for a stunning 552% upside potential in the next 12 months“With the launch of Dsuvia, we believe investor focus can now shift to launch metrics and peak sales potential for the product. As ACRX launches a true alternative to IV opioids, we expect investors to begin to appreciate the value of the product. We believe that Dsuvia offers an advancement in delivery of adequate pain treatment by eliminating the need for an invasive and time-consuming IV set-up in the emergency room, as well as an outpatient, or post-surgery, setting. Despite hospital launches taking time, we expect the uptake of Dsuvia to drive revenue upside beyond the Street's current estimates, which, in turn, could drive the stock higher from current levels,” Follked opined.

"TONGUE & DONE" NOT used since 2019! AcelRx's 8K they said "The Company believes it can easily address these concerns without a material impact to the Company given the nature of the Promotional Materials and because the Company has not used the Banner Ad since late 2019, nor used the table drape that is part of the Tabletop Display since November 2019.... The Company intends to respond to the FDA within the timeframe requested in the Letter and seek guidance and clarification from the FDA on the concerns raised in the Letter"

1st off, AcelRx was moving higher since January, hitting almost $3.00 prior to the TRULY B.S. FDA Warning Letter. HINT HINT to report any potential concerns with a drug: **The FDA encourages healthcare providers and consumers to report potentially false or misleading prescription drug promotion to FDA’s Bad Ad program.*** AcelRx last used this ad "Tongue and Done" in 2019:1st FDA CONCERN: "The promotional communications at issue, however, promote the product as simple to administer -- just “Tongue and Done.” This promotion dangerously undercuts FDA-required conditions on the proper administration of the drug, which requires particular diligence to minimize the risk of serious or even fatal adverse events."2nd FDA CONCERN: "For example, the materials state that patients may retake the drug in one-hour intervals but fail to state that the maximum daily dosage is 12 tablets in 24 hours. This omission is concerning due to the serious risks associated with overdose of Dsuvia, including respiratory depression and death."REALLY, these are the CONCERNS of the FDA with COVID-19 KILLING PEOPLE, etc. AcelRx RESPONSE per the 8K:"...the Company believes it can easily address these concerns without a material impact to the Company given the nature of the Promotional Materials and because the Company has not used the Banner Ad since late 2019, nor used the table drape that is part of the Tabletop Display since November 2019; however, the Company plans to review its marketing materials to identify any potential revisions in light of the Letter. The Company intends to respond to the FDA within the timeframe requested in the Letter and seek guidance and clarification from the FDA on the concerns raised in the Letter. The Letter does not restrict the Company’s ability to manufacture or sell DSUVIAhttps://ir.acelrx.com/static-files/944541d1-fd9c-49cb-a7e3-6e6e7d2add41

Why Big Pharma is nervous about DSUVIA!Aug. 19, 2020: "The standard of care for perioperative opioid administration has not been disrupted for over 100 years. We should no longer accept the rapid plasma fluctuations of IV bolus opioid administration as the status quo, as it impacts the patient's hemodynamic status and requires repeated redosing which ultimately results in higher overall opioid exposure"Dr. Christian Tvetenstrand, Chairman of Surgery and Director of Trauma, United Health Services Wilson Medical Center, New York. "I strongly believe this data on preoperative DSUVIA administration will result in a paradigm shift in pain management protocols across all ambulatory surgeries, as we have already seen significant cost savings due to less medical intervention and improved patient recovery."https://ir.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-announces-publication-clinical-data

still no response to FDA on the false advertising allegations, but vinnie did notify SEC afterhours that they passed out 387,500 free shares to the management team doing such a great job...

"FDA requests that AcelRx cease any violations of the Food, Drug and Cosmetic Act and submit a written response within 15 days from the date of receipt of the letter addressing the concerns in the letter, listing all other promotional communications that contain statements such as those described in the letter, and explaining any plan for discontinuing use of such communications or for ceasing distribution of Dsuvia."

I don't see the big deal in the FDA letter.. so they had a problem with some promotional material.. sounds pretty minor to me. Long here, still looking good to me.. and I believe the Nasdaq is calming down.

Time will tell if Vincent becomes a multi-millionaire from the 1m shares granted March 3rd!Angotti Vincent J.1,000,000 Shares (4) (5)4. On March 3, 2021, the Reporting Person was granted performance options subject to the satisfaction of share price targets over a performance period from March 3, 2021 to December 31, 2024 (the "PerformancePeriod"), as determined by the Compensation Committee (the "Committee") of the Company's Board of Directors.5. The performance options shall be earned as follows: (i) 33% of the performance options if the Company's average closing stock price measured over a period of thirty consecutive trading days within the PerformancePeriod equals or exceeds $4.00, (ii) an additional 33% of the performance option if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Periodequals or exceeds $5.00, and (iii) 34% of the performance options if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals orexceeds $6.00...https://ir.acelrx.com/static-files/b53becb4-3480-4924-88fe-a324712adce8